# Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors

> **NCT07524322** · PHASE1 · RECRUITING · sponsor: **Regor Pharmaceuticals Inc.** · enrollment: 63 (estimated)

## Conditions studied

- Breast Cancer
- Ovarian Cancer
- Endometrial Cancer
- PIK3CA Mutation
- HER2- Negative Breast Cancer
- Advanced Breast Cancer
- Unresectable Solid Tumor
- Hormone Receptor Positive Tumor
- Cervical Cancer

## Interventions

- **DRUG:** RGT-490

## Key facts

- **NCT ID:** NCT07524322
- **Lead sponsor:** Regor Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04
- **Primary completion:** 2028-04
- **Final completion:** 2028-10
- **Target enrollment:** 63 (ESTIMATED)
- **Last updated:** 2026-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07524322

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07524322, "Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-06 from https://api.ai-analytics.org/clinical/NCT07524322. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*